Study design and participants
COA, substance abuse, allergies
DISEASES, SARS-COV-2 INFECTION, ALLERGIES
This single-center, randomized, prospective, open-labelled, pilot cohort study enrolled healthy adults aged 18-60 years during September to December of 2021. Participants naïve for SARS-CoV-2 infection, capable of adhering to scheduled fractional dosing regimens, with an ability to understand Thai, and to self-report digitally were included in the study. Exclusion criteria included those that: were previously infected with SARS-CoV-2; received prophylactic or investigational COVID-19 treatment; received blood, plasma, immunoglobulins, or antibodies within 90 days of the study; had a history of severe drug or vaccine allergies, pre-existing comorbidities, underlying diseases, drug, or substance abuse; were pregnant; and were immunocompromised or receiving immunosuppressive agents. These study protocols were approved by the Human Research Protection Unit, Faculty of Medicine Siriraj Hospital, Mahidol University (COA: MU-MOU 704/2021) and registered under Thailand’s Clinical Trial Registry (registration number: TCTR20210904004, 